ストックスクリーナーアプリを入手
95.25
0.50%
-0.48
アフターアワーズ：
96.00
0.75
+0.79%
前日終値:
$95.73
開ける：
$95.17
24時間の取引高:
827.75K
Relative Volume:
0.73
時価総額：
$23.93B
収益：
$3.26B
当期純損益:
$-1.45B
株価収益率:
-16.22
EPS:
-5.871
ネットキャッシュフロー:
$1.18B
1週間 パフォーマンス:
-3.10%
1か月 パフォーマンス:
-8.20%
6か月 パフォーマンス:
+6.28%
1年 パフォーマンス:
-10.19%
1日の値動き範囲:
$93.92
$97.46
1週間の範囲:
$93.92
$100.02
52週間の値動き範囲:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
95.25 | 24.75B | 3.26B | -1.45B | 1.18B | -5.871 |
VRTX
Vertex Pharmaceuticals Inc
|
505.64 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
196.48 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
742.12 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
928.44 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
200.87 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-02 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | アップグレード | Goldman | Neutral → Buy |
| 2025-06-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-05-29 | 開始されました | Goldman | Neutral |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2025-01-10 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2024-11-19 | 開始されました | Berenberg | Buy |
| 2024-11-19 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-11-08 | アップグレード | Goldman | Neutral → Buy |
| 2024-09-24 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | アップグレード | Jefferies | Hold → Buy |
| 2024-09-16 | アップグレード | JP Morgan | Underweight → Neutral |
| 2024-08-07 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-08-02 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-14 | 開始されました | Evercore ISI | In-line |
| 2024-02-23 | 開始されました | BMO Capital Markets | Outperform |
| 2024-01-05 | 開始されました | Oppenheimer | Perform |
| 2023-12-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-10-16 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-17 | アップグレード | Redburn | Neutral → Buy |
| 2022-12-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-08-17 | 開始されました | Cowen | Market Perform |
| 2022-07-13 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2021-12-16 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-11-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 開始されました | Deutsche Bank | Hold |
| 2021-10-07 | 開始されました | Jefferies | Hold |
| 2021-08-11 | アップグレード | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-06-16 | ダウングレード | Redburn | Neutral → Sell |
| 2021-05-18 | 開始されました | Goldman | Neutral |
| 2021-05-11 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-08-03 | 再開されました | Berenberg | Buy |
| 2020-07-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-06-30 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 開始されました | H.C. Wainwright | Neutral |
| 2020-01-24 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | ダウングレード | UBS | Buy → Neutral |
| 2019-11-05 | 開始されました | Wolfe Research | Outperform |
| 2019-11-04 | 開始されました | Berenberg | Buy |
| 2019-11-04 | 開始されました | BofA/Merrill | Buy |
| 2019-11-04 | 開始されました | Canaccord Genuity | Buy |
| 2019-11-04 | 開始されました | JP Morgan | Overweight |
| 2019-11-04 | 開始されました | SVB Leerink | Outperform |
| 2019-11-04 | 開始されました | UBS | Buy |
すべてを表示
Biontech Se Adr (BNTX) 最新ニュース
BioNTech CEO sells 39,000 shares. BioNTech stock has a USD 126.00 average target - AD HOC NEWS
BioNTech SE (BNTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now? - TradingView
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast - GlobeNewswire Inc.
BioNTech SE (CEUX:22UAd)Valuation Measures & Financial Statistics - GuruFocus
BioNTech SE (BNTX) stock price, news, quote and history - Yahoo Finance Australia
BioNTech Balances Breakthrough Cancer Data Against a Messy Founder Split () - aktiencheck.de
BNTX Stock Quote Price and Forecast - CNN
Form 4 BioNTech SE For: 25 September - Investing.com India
BioNTech (BNTX) 10K Form and Latest SEC Filings 2026 - MarketBeat
BNTX Stock Price and Chart — NASDAQ:BNTX - tradingview.com
BioNTech SE (22UA.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
BioNTech Steps Deeper Into Lung Cancer With New Dareon-Rosetta35 Trial - TipRanks
eBay Upgraded, Airbnb Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech CEO Sahin Ugur Sells 49,000 Shares, Retains 553,209 Shares Post-Transaction - Kalkine Media
"MarketWatch" Features Halberd Corporation With Prominent Pharmaceutical Companies on New Treatments for COVID-19 - ACCESS Newswire
BioNTech's lung cancer drug outperforms chemo in clinical study - mugglehead.com
BioNTech's Oncology Credibility Test Comes Down to Four Days in Seoul () - aktiencheck.de
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit? - TradingView
BioNTech's Downsizing Signal: Factory Divestitures and a Trimmed Forecast Frame the Pipeline Debate - aktiencheck.de
Advanced Micro Devices Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech CEO Ugur Sahin Executes Sale of 76,500 Shares Under Rule 10b5-1 Plan - Kalkine Media
Why Pfizer Stock Was so Healthy in August - The Motley Fool
This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Why is BioNTech stock sliding today? - investing.com
BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development - Morningstar
BioNTech's Balancing Act: A COVID Lifeline Arrives Just as Oncology Investors Need a Reason to Stay - aktiencheck.de
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - easternprogress.com
BioNTech's High-Stakes Seoul Debut: A Cash-Rich Pivot Meets Its First Real Test () - aktiencheck.de
BioNTech's September Test: Can Oncology Data Outweigh a Shrinking COVID Franchise? () - aktiencheck.de
BioNTech SEADR (BNTX) Fundamental & Financial Data - Stocktwits
Biontech Se Adr (BNTX) 財務データ
収益
当期純利益
現金流量
EPS
Biontech Se Adr (BNTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sahin Ugur | Chief Executive Officer |
Oct 06 '26 |
Sale |
96.81 |
21,000 |
2,032,995 |
87,209 |
| Sahin Ugur | Chief Executive Officer |
Oct 01 '26 |
Sale |
97.46 |
17,000 |
1,656,745 |
197,209 |
| Sahin Ugur | Chief Executive Officer |
Oct 02 '26 |
Sale |
96.72 |
17,000 |
1,644,323 |
180,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 29 '26 |
Sale |
98.26 |
34,000 |
3,340,809 |
246,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 30 '26 |
Sale |
98.12 |
32,000 |
3,139,850 |
214,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 28 '26 |
Sale |
98.47 |
34,000 |
3,347,919 |
280,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 25 '26 |
Sale |
98.69 |
27,000 |
2,664,581 |
314,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 24 '26 |
Sale |
98.99 |
39,000 |
3,860,661 |
341,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 23 '26 |
Sale |
99.40 |
30,000 |
2,982,081 |
380,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 22 '26 |
Sale |
100.72 |
46,000 |
4,633,037 |
410,209 |
2.20%
0.57%
大文字化:
|
ボリューム (24 時間):